High-risk AI systems under the EU AI Act carry significant obligations for providers. Article 17 mandates a robust, documented Quality Management System (QMS) to ensure ongoing protection of health, safety and fundamental rights across the entire AI lifecycle, from design and data management to deployment, post-market monitoring, and decommissioning. This QMS must integrate risk management (per Article 9 and prEN 18228), handle modifications (especially for continuously learning systems), support conformity assessments, and enable traceability for fundamental rights, health, safety, and technical documentation.
EN 18286 (the draft harmonized standard for AI QMS under the EU AI Act) translates these requirements into auditable, product-centric processes. EN 18286 provides the engineering specification for conformity with Article 17. It emphasizes a lifecycle approach, integration with standards like ISO 13485 where possible, top-management accountability, data management and governance, cybersecurity, change control, incident reporting, and continuous improvement.
Selecting or validating an AI QMS software solution is critical. Generic tools often require heavy customization, leading to validation burdens and traceability gaps. Traditional QMS software primarily manages regulatory compliance risks without the in-depth focus on protecting health, safety and fundamental rights that the AI Act demands. The wrong solution will fail conformity assessment, delay market access, increase nonconformity findings during audits or conformity assessments, or expose providers to regulatory penalties.
Here are key questions to ask prospective QMS solution vendors, focusing on high-risk AI providers under the AI Act and EN 18286 requirements. These explore technical depth, scalability, integration, and practical support for regulatory obligations.
1. Is Your QMS Software Purpose-Built or Adapted for High-Risk AI Systems Under the EU AI Act?
Many platforms claim broad "compliance" support, but high-risk AI demands unique capabilities: managing probabilistic outputs, data quality for training/validation/test datasets, bias mitigation, human oversight interfaces, and controls for evolving systems (e.g., predetermined change management plans).
General enterprise tools may force workarounds that undermine proportionality or traceability.
Follow-up questions:
- What was the solution originally designed for, and which high-risk systems are covered (e.g., biometrics, critical infrastructure, employment, or medical AI)?
- How does it natively support EN 18286 clauses on design verification, data governance, and post-market monitoring?
- Can you demonstrate traceability matrices linking AI system components to Article 17 elements without extensive customization?
2. How Does Your Solution Align with Article 17 and EN 18286 Requirements?
The QMS must explicitly cover Article 17(1) elements: regulatory compliance strategy (including modifications and conformity assessment), design/development controls, testing/validation techniques, technical specifications, data management, risk management, post-market monitoring, incident reporting, communication with authorities, record-keeping, resource/supplier management, and accountability frameworks.
EN 18286 adds structure through quality policy, intended purpose, quality objectives, lifecycle processes, nonconformity handling, and continuous improvement.
Probe deeper:
- Which specific EN 18286 clauses or Article 17 subparagraphs are supported out-of-the-box (e.g., automated risk management per Art. 9 integration, dataset logging for representativeness and bias)?
- How do you handle updates to harmonized standards or AI Act guidance?
- What evidence (e.g., mapping documents) can you provide for conformity assessment?
3. Does the Software Scale with High-Risk AI Providers Across Development Stages and System Complexity?
High-risk AI providers range from startups with one system to enterprises managing portfolios across sectors and borders. The QMS must remain proportionate yet comprehensive, supporting iterative development, continuous learning models, and multi-jurisdictional compliance.
Ask about:
- Scalability from prototype to deployed high-risk systems (or expanded into new Annex III use cases).
- Support for portfolio-level oversight, variant management, and decommissioning processes.
- How the system maintains efficiency as data volumes, model complexity, or supply chain dependencies grow.
4. How Does the Solution Support Integrated Risk Management, Design Controls, and Traceability for AI-Specific Challenges?
Article 9 risk management must run throughout the lifecycle, identifying harms to health, safety, and fundamental rights. EN 18286 requires tight linkage to design verification/validation, especially for adaptive AI where changes are pre-planned and controlled.
Traceability is essential: from datasets ? model training ? outputs ? post-market events.
Key capabilities to verify:
- Bidirectional linking between risks, design elements, test results, and technical documentation.
- Support for bias/fairness assessments, robustness testing, and human oversight mechanisms.
- Automated impact assessments and residual risk documentation.
5. What Built-In Workflows Exist for Data Governance, Internal Controls, Cybersecurity Testing/Validation, Nonconformities, CAPA-Like Processes, and Change Management?
Data quality is foundational (relevance, representativeness, error-free as possible). Testing must cover foreseeable misuse and edge cases. EN 18286 and Article 17 demand systematic actions for nonconformities, corrective actions, and controlled modifications.
Evaluate:
- Dataset acquisition, labeling, storage, and retention workflows with audit trails.
- Validation protocols for static and dynamic (continuously learning) systems.
- Nonconformity/incident capture, root-cause analysis, and escalation to authorities (timelines per Article 73).
- Change management that distinguishes minor vs. substantial modifications triggering re-assessment.
6. How Does the QMS Enable Closed-Loop Post-Market Monitoring, Incident Reporting, and Continuous Improvement?
Post-market surveillance (Article 72) must feed back into risk management and design updates. Providers need real-time performance monitoring, serious incident reporting, and mechanisms to update the QMS iteratively.
Look for:
- Integration of logs, user feedback, and external data into risk files and technical documentation.
- Automated alerts for performance degradation or emerging risks.
- Support for corrective/preventive actions that close the loop across the AI lifecycle.
- Record-keeping for at least the required retention periods, with easy retrieval for authorities.
7. Can the Solution Facilitate Efficient Conformity Assessments and Audits (Including Paperless/Remote Readiness)?
Conformity assessment for high-risk systems (internal or third-party) relies on comprehensive, accessible documentation. EN 18286 emphasizes auditable evidence.
Questions:
- How does it generate or export technical files, QMS procedures, and traceability evidence on demand?
- Can it generate reports for notified bodies or national authorities when requested?
- Features for version control, electronic signatures, and secure sharing that support remote or hybrid audits.
8. What Expertise Does the Vendor Team Have in AI Act Compliance, High-Risk AI, and EN 18286?
Beyond software, you need partners who understand AI-specific nuances (e.g., explainability, fundamental rights impacts) and regulatory evolution.
Inquire:
- Do support, implementation, and customer success teams include AI engineers, risk specialists, or former notified body auditors with EU AI Act experience?
- Can they provide guidance on integrating with existing ISO frameworks or sector-specific rules (e.g., medical devices under MDR, ISO 42001 and governance frameworks)?
- Availability of training, templates, or consulting aligned with EN 18286.
9. How Rapid and Structured Is Implementation, Including Validation Support?
Implementation timelines matter for time-to-market. The solution should include validation aids (e.g., for software as a tool supporting regulated AI development) and tailored plans.
Ask:
- Typical timelines and phased rollout (e.g., core QMS setup ? AI-specific modules ? full integration).
- Built-in or included tools for system validation and ongoing re-validation.
- Customization vs. configuration balance to minimize validation burden.
10. What Data Security, Confidentiality, and Sovereignty Measures Are in Place?
AI data is highly sensitive (IP, personal data, training datasets). The QMS tool itself must be secure and support compliance with GDPR, cybersecurity requirements, and AI Act record-keeping.
Verify:
- AI-specific controls (e.g., secure enclaves for datasets).
- Data residency options for EU sovereignty.
- Audit rights and breach notification processes.
11. Is Ongoing Support, Updates, and Validation Assistance Included Without Hidden Costs?
Regulatory landscapes evolve; your QMS software must keep pace with AI Act amendments, new harmonized standards, and guidance.
Final checks:
- Frequency of regulatory-aligned updates and how they are rolled out.
- Inclusion of validation maintenance, user training, and enhancements tied to EN 18286 evolutions.
- Long-term partnership model with clear SLAs for compliance support.
Selecting the right QMS solution positions high-risk AI providers not just for compliance but for building trustworthy, resilient systems that protect users and gain competitive advantage through demonstrated rigor. Prioritize vendors who treat Article 17 and EN 18286 as core design principles rather than add-ons. Thorough vendor evaluation, including demos with your specific AI use cases and reference checks, is essential before commitment.
This approach ensures your QMS is a living, integrated framework that drives quality, mitigates risks proactively, and supports sustainable innovation under the EU AI Act.